Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2023 Apr;28(2):122-130.
doi: 10.1177/1358863X231154951.

Outcomes among patients with peripheral artery disease in the Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-Term Effectiveness (ADAPTABLE) study

E Hope Weissler  1 , Amanda Stebbins  1 , Lisa Wruck  1 , Daniel Muñoz  2 , Kamal Gupta  3 , Saket Girotra  4 , Jeff Whittle  5 , Catherine P Benziger  6 , Tamar S Polonsky  7 , Steven M Bradley  8 , Bradley G Hammill  1 , James G Merritt  9 , Doris N Zemon  10 , Adrian F Hernandez  1 , W Schuyler Jones  1
Affiliations
Randomized Controlled Trial

Outcomes among patients with peripheral artery disease in the Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-Term Effectiveness (ADAPTABLE) study

E Hope Weissler et al. Vasc Med. 2023 Apr.

Abstract

Background: We aimed to understand the effects of aspirin dose on outcomes in patients with peripheral artery disease (PAD) as well as their participation in a pragmatic randomized controlled trial.

Methods: In a subanalysis of the Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-Term Effectiveness (ADAPTABLE) study, we compared aspirin doses (81 vs 325 mg) among participants with PAD and study participation metrics in patients with and without PAD. The primary outcome composite was all-cause mortality, nonfatal myocardial infarction, and nonfatal stroke.

Results: Among 14,662 participants enrolled in ADAPTABLE with PAD status available, 3493 (23.8%) had PAD. Participants with PAD were more likely to experience the primary composite (13.76% vs 5.31%, p < 0.001), all-cause mortality (7.55% vs 3.01%, p < 0.001), myocardial infarction (5.71% vs 2.09%, p < 0.001), stroke (2.45% vs 0.86%, p < 0.001), and major bleeding (1.19% vs 0.44%, p < 0.001). A higher aspirin dose did not reduce the primary outcome in patients with PAD (13.68% vs 13.84% in 81 mg and 325 mg groups; OR 1.05, 95% CI 0.88-1.25). Participants with PAD were less likely to enroll via email (33.0% vs 41.9%, p < 0.0001), less likely to choose internet follow-up (79.2% vs 89.5%, p < 0.0001), and were more likely to change their aspirin doses (39.7% vs 30.7%, p < 0.0001).

Conclusions: ADAPTABLE participants with PAD did not benefit from a higher dose of aspirin and participated in the study differently from those without PAD. These results reinforce the need for additional PAD-specific research and suggest that different trial strategies may be needed for optimal engagement of patients with PAD. (ClinicalTrials.gov Identifier: NCT02697916).

Keywords: antiplatelet therapy; clinical trial methodology; evidence-based medicine; peripheral artery disease (PAD); pragmatic trials.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest:

The authors have no relevant conflicts of interest.

Similar articles

See all similar articles

References

    1. Weissler EH, Jones WS, Desormais I, et al. Polyvascular disease: A narrative review of current evidence and a consideration of the role of antithrombotic therapy. Atherosclerosis. Dec 2020;315:10–17. doi:10.1016/j.atherosclerosis.2020.11.001 - DOI - PubMed
    1. Aboyans V, Ricco JB, Bartelink MEL, et al. Editor’s Choice - 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg. Mar 2018;55(3):305–368. doi:10.1016/j.ejvs.2017.07.018 - DOI - PubMed
    1. Bonaca MP, Bauersachs RM, Anand SS, et al. Rivaroxaban in Peripheral Artery Disease after Revascularization. N Engl J Med. May 21 2020;382(21):1994–2004. doi:10.1056/NEJMoa2000052 - DOI - PubMed
    1. Conte MS, Pomposelli FB. Society for Vascular Surgery Practice guidelines for atherosclerotic occlusive disease of the lower extremities management of asymptomatic disease and claudication. Introduction. J Vasc Surg. Mar 2015;61(3 Suppl):1S. doi:10.1016/j.jvs.2014.12.006 - DOI - PubMed
    1. Jones WS, Mulder H, Wruck LM, et al. Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease. N Engl J Med. May 27 2021;384(21):1981–1990. doi:10.1056/NEJMoa2102137 - DOI - PMC - PubMed

Publication types

MeSH terms

Associated data